SEARCH

SEARCH BY CITATION

References

  • 1
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988–96. N Engl J Med 2000; 342 (9): 605612.
  • 2
    Cosio FG, Pelletier RP, Falkenhain ME et al. Impact of acute rejection and early allograft function on renal allograft survival. Transplantation 1997; 63 (11): 16111615.
  • 3
    Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70 (7): 10981100.
  • 4
    Matas AJ, Humar A, Gillingham KJ et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62 (2): 704714.
  • 5
    Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331 (6): 365376.
  • 6
    Gebauer BS, Hricik DE, Atallah A et al. Evolution of the enzyme-linked immunosorbent spot assay for post- transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2 (9): 857866.
  • 7
    Heeger PS, Greenspan NS, Kuhlenschmidt S et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163 (4): 22672275.
  • 8
    Tary-Lehmann M, Hricik DE, Justice AC, Potter NS, Heeger PS. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998; 66 (2): 219224.
  • 9
    Heeger PS, Hricik D. Immune monitoring in kidney transplant recipients revisited. J Am Soc Nephrol 2002; 13 (1): 288290.
  • 10
    Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344 (13): 947954.
  • 11
    Rush D, Somorjai R, Deslauriers R, Shaw A, Jeffery J, Nickerson P. Subclinical rejection – a potential surrogate marker for chronic rejection – may be diagnosed by protocol biopsy or urine spectroscopy. Ann Transplant 2000; 5 (2): 4449.
  • 12
    Nickerson P, Jeffery J, Gough J et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9 (3): 482487.
  • 13
    Kasiske BL. Clinical correlates to chronic renal allograft rejection. Kidney Int Suppl 1997; 63: S71S74.
  • 14
    Cosio FG, Falkenhain ME, Pesavento TE et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997; 29 (3): 419427.
  • 15
    Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients. Implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001; 167 (12): 71997206.
  • 16
    Vella JP, Spadafora-Ferreira M, Murphy B et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64 (6): 795800.
  • 17
    Ciubotariu R, Liu Z, Colovai AI et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101 (2): 398405.
  • 18
    Ng WF, Hernandez-Fuentes M, Baker R, Chaudhry A, Lechler RI. Reversibility with interleukin-2 suggests that T cell anergy contributes to donor-specific hyporesponsiveness in renal transplant patients. J Am Soc Nephrol 2002; 13 (12): 29832989.
  • 19
    VanBuskirk AM, Ferguson RM, Orosz CG. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2 (2): 134141.
  • 20
    Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73 (8): 12691273.
  • 21
    Murphy B. Genetic polymorphisms and transplantation. Am J Kidney Dis 2001; 38 (5): 11151118.
  • 22
    Filler G, Hocher B. The emerging role of gene polymorphisms determining outcome after solid- organ transplantation. Pediatr Transplant 2002; 6 (1): 1214.
  • 23
    Hricik DE, Heeger PS. Minimization of immunosuppression in kidney transplantation. The need for immune monitoring. Transplantation. 2001; 72 (8 Suppl.): S32S35.
  • 24
    Mayer TG, Fuller AA, Fuller TC, Lazarovits AI, Boyle LA, Kurnick JT. Characterization of in vivo-activated allospecific T lymphocytes propagated from human renal allograft biopsies undergoing rejection. J Immunol 1985; 134 (1): 258264.
  • 25
    Ashwell JD, Chen C, Schwartz RH. High frequency and nonrandom distribution of alloreactivity in T cell clones selected for recognition of foreign antigen in association with self class II molecules. J Immunol 1986; 136 (2): 389395.
  • 26
    Kerman RH, Kahan BD.Immunological evaluation of transplant rejection: pre and postoperative indices detecting immune responsiveness. Ann Clin Res 1981; 13 (4–5): 244263.
  • 27
    Kerman RH, Floyd M, Van Buren C, McConnell BJ, McConnell R, Kahan BD. Correlation of nonspecific immune monitoring with rejection or impaired function of renal allografts. Transplantation 1981; 32 (1): 1623.
  • 28
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62 (1): 311318.
  • 29
    Fink JC, Salmanullah M, Blahut SA et al. The inevitability of renal function loss in patients with hypercreatinemia. Am J Nephrol 2001; 21 (5): 386389.